CLAIMS

1. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma, wherein lurbinectedin is administered as a monotherapy.

2. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma, wherein the malignant mesothelioma is malignant pleural mesothelioma.

3. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma, wherein the malignant mesothelioma is malignant peritoneal mesothelioma.

4. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma; wherein lurbinectedin treatment excludes treatment with a combination of lurbinectedin and a platinum agent.

5. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma, wherein lurbinectedin treatment excludes a combination of lurbinectedin and cisplatin.

6. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof as sole chemotherapy agent for use in the treatment of malignant mesothelioma.

7. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to any preceding claim, wherein the malignant mesothelioma is progressive.

8. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to claim 7, wherein the malignant mesothelioma has progressed from first-line therapy, preferably standard first-line therapy.

9. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to claim 8, wherein the first-line therapy is platinum-pemetrexed chemotherapy.

10. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to claim 9, wherein the platinum-pemetrexed chemotherapy is with surgery.

11. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to claim 9 or claim 10, wherein the first-line therapy also includes radiotherapy.

12. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to claim 8, wherein the first-line therapy is an immunotherapy, preferably an anti-PD-1, anti-PD-L1 or anti CTLA-4 therapy, or combinations thereof.

13. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to claim 8, wherein the first-line therapy is platinum-pemetrexed chemotherapy and an immunotherapy, preferably an anti-PD-1, anti-PD-L1 or anti CTLA-4 therapy, of combinations thereof.

14. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma; wherein lurbinectedin is the sole chemotherapy agent; and wherein lurbinectedin is administered following immunotherapy; preferably an anti-PD-1, anti-PD-L1 or anti CTLA-4 therapy, or combinations thereof.

15. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to claim 8, wherein the first-line therapy is an anti-angiogenesis therapy.

16. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to claim 15, wherein the anti-angiogenesis therapy is a VEGF inhibitor, such as bevacizumab.

17. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to any preceding claim, wherein the treatment is a third-line therapy; and wherein the previous lines of therapy may be selected from the therapies in claims 7 to 16, including where the first line therapy is

platinum-pemetrexed chemotherapy as claimed in any one of claims 9 to 11, and the second line therapy is immunotherapy.

18. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to any preceding claim, wherein lurbinectedin is administered once every one to four weeks, preferably once every three weeks.

19. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to any preceding claim, wherein lurbinectedin is administered at a dose of 1 to 5 mg/m^2 body surface area, 2 to 3 mg/m^2 body surface area, about 3 mg/m^2 body surface area, 3 to 3.5 mg/m^2 body surface area, or 3.2 mg/m^2 body surface area.

20. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to any preceding claim, wherein lurbinectedin is administered as an infusion, preferably with an infusion time of up to 24 hours, 1 to 12 hours, 1 to 6 hours and most preferably 1 hour.

21. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to any preceding claim, wherein the patient is additionally treated with radiotherapy.

22. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to claim 18, wherein the radiotherapy is administered prior to or subsequent to administration of lurbinectedin or a pharmaceutically acceptable salt or ester thereof, preferably at least an hour, three hours, five hours, 12 hours, a day, a week, a month, more preferably several months (e.g. up to three months) prior or subsequent to administration of lurbinectedin or a pharmaceutically acceptable salt or ester thereof.

23. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to any preceding claim, wherein the patient is additionally treated with an anti-emetic, G-CSF and/or GM-CSF

24. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to any preceding claim, wherein the patient is additionally treated with G-CSF.

25. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to any one of claims 1 to 24, wherein the malignant mesothelioma is epithelioid mesothelioma.

26. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to any one of claims 1 to 24, wherein the malignant mesothelioma is sarcomatoid mesothelioma.

27. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to any one of claims 1 to 24, wherein the malignant mesothelioma is biphasic mesothelioma.

28. Lurbinectedin or a pharmaceutically acceptable salt or ester thereof for use in the treatment of malignant mesothelioma according to any preceding claim, wherein the pharmaceutically acceptable salt is selected from the hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, maleate, fumarate, citrate, oxalate, succinate, tartrate, malate, mandelate, methanesulfonate *p*-toluenesulfonate, sodium, potassium, calcium and ammonium salts, ethylenediamine, ethanolamine, *N,N*-dialkylenethanolamine, triethanolamine and basic aminoacids salts.

29. A kit comprising lurbinectedin or a pharmaceutically acceptable salt or ester thereof together with instructions for treating malignant mesothelioma.